Sleep onset improvement
Multiple RCTs show valerian reduces time to fall asleep (sleep latency) by an average of 15–20 minutes and improves subjective sleep quality without the dependency or grogginess associated with pharmaceutical sedatives.
Anxiety reduction
Valerenic acid produces anxiolytic effects comparable to low-dose benzodiazepines in clinical studies, reducing anxiety symptoms without significant sedation at daytime doses.
Stress relief
Valerian reduces physiological stress responses including heart rate variability changes and cortisol levels during acute stressors, supporting use as a daytime adaptogen at lower doses.
Menopausal symptom support
RCTs in postmenopausal women show valerian reduces hot flash frequency and severity, and improves sleep quality disrupted by hormonal changes.
GABA-A receptor modulation
Valerenic acid binds GABA-A receptor beta subunits as a positive allosteric modulator — similar mechanism to benzodiazepines but with lower affinity and without dependency risk.
GABA transaminase inhibition
Valerian extract inhibits GABA-T, the enzyme responsible for breaking down GABA in the synaptic cleft, increasing GABA availability and duration of action in the CNS.
Adenosine receptor interaction
Some valerian constituents (hesperidin, linarin) act on adenosine A1 receptors, which mediate sleep pressure and sedation as part of the natural sleep-wake regulatory system.
Meta-analysis of 16 RCTs examining valerian root extract for subjective sleep quality improvement.
1,093 patients across 16 RCTs.
Valerian significantly improved subjective sleep quality without producing side effects. Subjects were twice as likely to report good sleep with valerian vs. placebo.
RCT of valerian 255 mg three times daily vs. placebo in 68 postmenopausal women for 8 weeks.
68 postmenopausal women with hot flashes. 8-week intervention.
Significant reduction in hot flash frequency (50% vs. 5% placebo) and severity. Improved sleep quality scores. No serious adverse effects.